This is called, aptly, obstructive hypertrophic cardiomyopathy. This kind of obstruction is behind many of the more ...

Edgewise Therapeutics (NASDAQ: EWTX) is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, ...

Edgewise Therapeutics has announced positive top-line findings from two clinical trials where its EDG-7500 showed benefit as ...

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today and set a price ...

Shares in Edgewise Therapeutics rose after the company said it received positive top-line data in trials of its heart-disease treatment EDG-7500. Shares were up 25% in premarket trading to $23.91. The ...

Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...

Edgewise Therapeutics announced topline data from Phase 1 and Phase 2 trials of EDG-7500 for obstructive hypertrophic ...

Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular ...

H.C. Wainwright's reiteration of the Buy rating and the $90 price target for Cytokinetics reflects confidence in the clinical advancement of EDG-7500 and its potential to meet the unaddressed medical ...

Ho Chi Minh City is currently facing a critical shortage of radiopharmaceuticals needed for PET/CT scans, crucial in ...

Shinhan Life Vietnam supported youngsters undergoing leukemia treatment by providing VNĐ150 million worth of medical expenses ...

The treatment of heart failure itself—rather than the disease that causes heart failure, like HCM—tends to focus on the treatment of congestive heart failure, specifically. Cardiologists will ...